Current status and problems in the diagnosis and treatment of premenstrual syndrome and premenstrual dysphoric disorder from the perspective of obstetricians and gynecologists in Japan

To investigate the current status and problems in the diagnosis and treatment of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) from the perspective of obstetricians and gynecologists (OB/GYNs) in Japan, the Japanese Society of Obstetrics and Gynecology (JSOG) conducted a national‐wide survey.

[1]  Takashi Takeda,et al.  Psychometric Testing of the Premenstrual Symptoms Questionnaire and the Association Between Perceived Injustice and Premenstrual Symptoms: A Cross-Sectional Study Among Japanese High School Students , 2020, International journal of women's health.

[2]  B. Tran,et al.  Overview of Stigma against Psychiatric Illnesses and Advancements of Anti-Stigma Activities in Six Asian Societies , 2019, International journal of environmental research and public health.

[3]  M. Tohyama,et al.  Antidepressive Effects of Kamishoyosan through 5-HT1AReceptor and PKA-CREB-BDNF Signaling in the Hippocampus in Postmenopausal Depression-Model Mice , 2019, Evidence-based complementary and alternative medicine : eCAM.

[4]  T. Baba,et al.  Guidelines for office gynecology in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition , 2019, The journal of obstetrics and gynaecology research.

[5]  M. DelBello,et al.  Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management. , 2018, Current problems in pediatric and adolescent health care.

[6]  M. Fleck,et al.  Premenstrual Syndrome Diagnosis: A Comparative Study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST) , 2017, Revista Brasileira de Ginecologia e Obstetricia / RBGO - Gynecology and Obstetrics.

[7]  K. Yonkers,et al.  Premenstrual disorders , 2017, American journal of obstetrics and gynecology.

[8]  S. Nambiar,et al.  Management of Premenstrual Syndrome , 2017, BJOG: an International Journal of Obstetrics and Gynaecology.

[9]  J. Endicott,et al.  Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder , 2016, Archives of Women's Mental Health.

[10]  O. Takahashi,et al.  Contraception in Japan: Current trends. , 2016, Contraception.

[11]  S. Sigmon,et al.  Does a Disconnect Occur Between Research and Practice for Premenstrual Dysphoric Disorder (PMDD) Diagnostic Procedures? , 2014, Women & health.

[12]  G. Thornicroft,et al.  Review of mental‐health‐related stigma in Japan , 2013, Psychiatry and clinical neurosciences.

[13]  E. Wang,et al.  Burden of menstrual symptoms in Japanese women: results from a survey-based study , 2013, Journal of medical economics.

[14]  N. Yaegashi,et al.  Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines , 2012, International Journal of Clinical Oncology.

[15]  W. Biggs,et al.  Premenstrual syndrome and premenstrual dysphoric disorder. , 2011, American family physician.

[16]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[17]  Y. Akimoto,et al.  Fulfillment of the premenstrual dysphoric disorder criteria confirmed using a self-rating questionnaire among Japanese women with depressive disorders , 2011, BioPsychoSocial medicine.

[18]  A. Rapkin,et al.  Ethinyl estradiol 20 μg/drospirenone 3 mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder , 2011, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  J. Endicott,et al.  Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus , 2011, Archives of Women's Mental Health.

[20]  M. Steiner,et al.  Premenstrual dysphoric disorder: burden of illness and treatment update. , 2008, Journal of psychiatry & neuroscience : JPN.

[21]  K. Tasaka,et al.  Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in Japanese women , 2006, Archives of Women's Mental Health.

[22]  G. Bachmann,et al.  Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. , 2005, Contraception.

[23]  A. Wein.  Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials , 2005, BMJ : British Medical Journal.

[24]  D. Healy,et al.  Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. , 2005 .

[25]  C. Soares,et al.  Efficacy and Tolerability of Premenstrual Use of Venlafaxine (Flexible Dose) in the Treatment of Premenstrual Dysphoric Disorder , 2004, Journal of clinical psychopharmacology.

[26]  N. Suzuki.  Complementary and Alternative Medicine: a Japanese Perspective , 2004, Evidence-based complementary and alternative medicine : eCAM.

[27]  M. Steiner,et al.  The premenstrual symptoms screening tool (PSST) for clinicians , 2003, Archives of Women’s Mental Health.

[28]  L. Barbour,et al.  ACOG practice bulletin , 2001 .

[29]  K. Merikangas,et al.  The epidemiology of perimenstrual psychological symptoms , 2001, Acta psychiatrica Scandinavica.

[30]  L. Lopez,et al.  Oral contraceptives containing drospirenone for premenstrual syndrome. , 2009, The Cochrane database of systematic reviews.

[31]  J. Endicott,et al.  Daily Record of Severity of Problems (DRSP): reliability and validity , 2005, Archives of Women's Mental Health.

[32]  Jacob Cohen.  QUANTITATIVE METHODS IN PSYCHOLOGY A Power Primer , 1992 .

[33]  D. Rubinow,et al.  Premenstrual syndromes: overview from a methodologic perspective. , 1984, The American journal of psychiatry.